Diagnosing Your Jaw Type: Muscular vs Skeletal
The jaw looks wide for one of two anatomical reasons — or both simultaneously. Distinguishing them before treatment is not optional; it determines whether Botox, surgery, or a combination is appropriate.
The masseter muscle (마사지 근육, masaji geunyuk — the large chewing muscle on each side of the jaw) sits over the lower jaw bone. When this muscle is hypertrophied (enlarged due to genetics or habitual clenching), it adds visible width to the lower face. This is the muscular component — and it is the only component Botox can address.
The mandible angle (하악각, hawakgak — the bony corner where the jaw turns from vertical to horizontal) varies in prominence by genetics. A wide, flared, or squared mandible angle adds skeletal width to the jaw. Botox has no effect on bone.
The clinical test: Look straight ahead at a mirror and relax your jaw. Now clench your back teeth firmly. If your jaw visibly widens or bulges during the clench, the masseter muscle is contributing to the width. If the jaw looks similarly wide whether relaxed or clenched, the bone is the primary cause.
This test is a useful starting point, not a diagnosis. Many patients have both components — a squared mandible angle and hypertrophied masseter — and the test cannot distinguish the relative contribution of each. Korean clinics performing jaw surgery routinely obtain a facial CT scan (computed tomography — a three-dimensional X-ray of bone structure) before recommending surgery. CT imaging shows the exact bone morphology and distinguishes skeletal from muscular width definitively.
Board-certified plastic surgeons in Korea, certified by the 대한성형외과학회 (Daehan Seonghyeong Oegwa Haghoe — Korean Society of Plastic and Reconstructive Surgeons, or KSPRS), are the appropriate specialists for this assessment.¹
Side-by-Side Comparison
| Factor | Masseter Botox | Jaw Reduction Surgery |
|---|---|---|
| What it treats | Muscular jaw width (masseter hypertrophy) | Skeletal jaw width (mandible angle) |
| Result | Softer jaw contour; 3–6mm reduction in muscle bulk | Permanent bone reduction; 5–12mm reduction at jaw angle |
| Longevity | 4–6 months per session; gradual atrophy over 2–3 years of repeat treatment | Permanent — bone does not regenerate |
| Recovery | None — return to normal activity same day | 12–14 days in Korea; swelling arc 3–6 months |
| Cost (KRW) | ₩150,000–400,000 per session | ₩5,000,000–10,000,000 one-time |
| Cost (USD / AUD) | ≈$110–295 / ≈$170–450 per session | ≈$3,700–7,400 / ≈$5,600–11,200 one-time |
| Candidacy | Muscular component confirmed; patients who prefer non-surgical approach | Skeletal component confirmed on CT; KSPRS board-certified surgeon required¹ |
| Primary risks | Asymmetry; over-weakening of chewing function; result reversal if under-dosed | Swelling, nerve numbness (usually temporary), asymmetry, infection, general anaesthesia risks |
Both interventions are performed routinely in Seoul’s major aesthetic medicine districts. The KSPRS maintains a public registry where patients can verify a surgeon’s board certification before proceeding with jaw surgery.¹
Long-Term Cost Comparison
The per-session cost of Botox is low; the cumulative cost over years of maintenance is not.
A patient maintaining masseter Botox at two sessions per year pays ₩300,000–800,000 per year (≈$220–590 / ≈$335–890 AUD). Over five years, cumulative spend reaches ₩1,500,000–4,000,000 (≈$1,110–2,960 / ≈$1,670–4,450 AUD). Over ten years: ₩3,000,000–8,000,000 (≈$2,220–5,925 / ≈$3,330–8,900 AUD).
Jaw reduction surgery costs ₩5,000,000–10,000,000 (≈$3,700–7,400 / ≈$5,600–11,200 AUD) once, with no maintenance cost for the bone result. Patients who also have Botox post-surgery for residual muscular component pay session costs for that component only.
The crossover point — where cumulative Botox cost equals surgery cost — falls at roughly 6–13 years for most patients, depending on session frequency and clinic pricing. For patients under 35 with confirmed skeletal jaw squareness and a long maintenance horizon, the lifetime economics of surgery are competitive with indefinite Botox. For patients over 45, or those with purely muscular jaw width, Botox remains the lower-total-cost option over a realistic treatment horizon.
Cost should not be the primary decision driver — anatomy is. But for confirmed surgical candidates, the economics of surgery are not as unfavorable as the upfront price suggests.
When Surgery Is the Only Answer
Three situations make jaw reduction surgery the only clinically appropriate intervention:
1. Purely skeletal jaw width. If the mandible angle is wide, flared, or squared and the masseter muscle is normal in size, Botox produces no visible change. CT imaging confirms this. Injecting Botox into a normal-sized masseter risks weakening chewing function without delivering the jaw slimming result the patient seeks.
2. Botox trial with no response. A full therapeutic trial — 25–30 units per side, assessed at 6–8 weeks — that produces no visible jaw narrowing confirms the skeletal component is dominant. This is a reliable diagnostic result: Botox has worked pharmacologically (the muscle is weakened) but the jaw looks the same because bone, not muscle, is setting the jaw width.
3. Desired result exceeds what Botox can achieve. For patients seeking a 7mm+ reduction in jaw width, Botox alone cannot reach this threshold regardless of dose. Surgery is the only intervention that produces bone-level change.
KSPRS board certification requires six years of medical school, a four-year plastic surgery residency, and passage of KSPRS board examinations.¹ Patients should verify certification via the KSPRS public registry before proceeding with jaw reduction surgery.¹
Can I try Botox first before deciding on jaw surgery in Korea?
Yes — and this is often the recommended approach for patients uncertain about the cause or who want to experience jaw slimming before committing to surgery. A full therapeutic trial (25–30 units per side) reveals the muscular component. Satisfying results suggest surgery may be unnecessary; minimal change confirms the skeletal component is dominant. Botox does not prevent or complicate subsequent surgery — it is a safe diagnostic and therapeutic trial.
Does jaw reduction surgery in Korea remove the masseter muscle?
No — jaw reduction surgery operates on the bone (mandible angle), not the masseter muscle. The masseter is elevated off the bone to access the surgical site and then repositioned; it is not removed or significantly altered. Some patients receive Botox into the masseter at the same time as or after surgery to address any residual muscular component. The surgical result is bone-level change.
How much jaw narrowing can Botox achieve versus surgery in Korea?
Botox for primarily muscular jaw squareness: typically 3–6mm reduction in jaw width at the widest point, visible at 6–8 weeks. Surgery for skeletal jaw squareness: 5–12mm reduction depending on bone structure, visible progressively over 3–6 months as swelling resolves. The measurements are not directly comparable — Botox reduces soft tissue (muscle), surgery reduces bone. Combination treatment produces the largest total reduction for patients with both components.
References
¹ Korean Society of Plastic and Reconstructive Surgeons (KSPRS; 대한성형외과학회). Board Certification Registry. [ksprs-registry-org-identity], [ksprs-registry-training-requirements], [ksprs-registry-public-verification], [ksprs-registry-legal-requirement]. https://www.plasticsurgery.or.kr/